14 results on '"Marijt-van der Kreek T"'
Search Results
2. Donor vigilance: progress and challenges
- Author
-
Wiersum-Osselton, J. C., Marijt-van der Kreek, T., and de Kort, W. L. A. M.
- Published
- 2012
- Full Text
- View/download PDF
3. Donors' health state the year after peripheral haematopoietic progenitor cell collection: A prospective follow-up study in related and unrelated donors compared to first-time platelet donors
- Author
-
Bank, I., Wiersum-Osselton, J.C., Walraven, S.M. van, Netelenbos, T., Fechter, M., Marijt-van der Kreek, T., Bar, B.M.A.M., Bom, J.G. Van Der, and Brand, A
- Subjects
Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] - Abstract
Item does not contain fulltext Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral haematopoietic progenitor cells collected by apheresis (HPC-A) are the most common source used for allogeneic hematopoietic stem cell transplantation (HSCT). Retrospective short and long-term donor follow-up studies show very low risks of serious complications and do not report compelling evidence of increased cancer occurrence. Some studies reported a prolonged period of leucopenia without an obvious association with infectious complications. However, beyond the first few weeks after the procedure a relationship between events is elusive. We therefore evaluated medical service utilization by prospectively recruited HPC-A donors and first-time platelet apheresis donors for comparison for 1 year after donation. Data were prospectively collected using questionnaires and by medical record review. A total of 215 HPC-A donors (111 unrelated donors and 104 related donors) and 96 first-time platelet donors consented to participation in the study. Follow-up was available for 202 (96%): questionnaires were returned by 74% and records from nonstudy contacts were available for 94% of donors. During the 1-year follow-up, 94 of the donors who returned questionnaires sought medical attention for diagnostic evaluation and/or treatment: 41% of HPC-A donors and 40% of platelet donors. Medical service utilization the first year after HPC-A donation is similar to that after first-time platelet donation. The occurrence of serious medical conditions in both related and unrelated HPC-A donors underscores the importance of participation in long-term follow-up in large cohorts. The findings in this relatively small cohort contribute to evidence on the safety of G-CSF mobilization and HPC-A. J. Clin. Apheresis 31:523-528, 2016. (c) 2015 Wiley Periodicals, Inc.
- Published
- 2016
4. Risk factors for complications in donors at first and repeat whole blood donation: a cohort study with assessment of the impact on donor return
- Author
-
Wiersum-Osselton, J.C., Marijt-van der Kreek, T., Brand, A., Veldhuizen, I., Bom, J.G. van der, and Kort, W. de
- Subjects
donor retention ,vasovagal reaction ,needle-related complication ,blood donation ,first-time donor - Published
- 2014
5. Recording Donor Complications in Routine Donor Center Practice: Implementation of Improved Coding System
- Author
-
Wiersum-Osselton, J.C., Marijt-van der Kreek, T., Dongen, R. van, Bom, J.G. van der, and Kort, W. de
- Published
- 2011
6. Donor vigilance: a global update
- Author
-
Wiersum-Osselton, J. C., primary, Marijt-van der Kreek, T., additional, Bokhorst, A. G., additional, and de Kort, W. L. A. M., additional
- Published
- 2014
- Full Text
- View/download PDF
7. Plasmapheresis in healthy donors in the Netherlands: Cohort study of risk factors for donor complications
- Author
-
Wiersum-Osselton, J.C., primary, Marijt-van der Kreek, T., additional, and van Dongen, R., additional
- Published
- 2013
- Full Text
- View/download PDF
8. Blood donor screening in the Netherlands: Universal anti-HBc screening in combination with HBV nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing.
- Author
-
van de Laar TJ, Hogema BM, Molenaar-de Backer MW, Marijt-van der Kreek T, and Zaaijer HL
- Subjects
- Adult, DNA, Viral blood, Hepatitis B blood, Hepatitis B diagnosis, Hepatitis B virus genetics, Hepatitis B virus immunology, Humans, Netherlands, Unnecessary Procedures, Viremia diagnosis, Viremia virology, Blood Donors, Blood Safety, Donor Selection, Hepatitis B prevention & control, Hepatitis B Antibodies blood, Hepatitis B Core Antigens immunology, Hepatitis B Surface Antigens blood, Hepatitis B virus isolation & purification, Nucleic Acid Amplification Techniques, Viremia blood
- Abstract
Background: In the Netherlands, blood donor screening for hepatitis B virus (HBV) consists of HBsAg screening since the 1970s, HBV DNA minipool testing (MP-NAT) since 2008, and anti-HBc screening since 2011. Anti-HBc reactivity causes deferral only if anti-HBs titers are <200 IU/mL, or when anti-HBc was acquired during follow-up., Study Design and Methods: Over 5.5 million donations from 582,459 Dutch donors were screened for HBV DNA, HBsAg, anti-HBc, and, if anti-HBc positive, also for anti-HBs. The added value, expressed as the yield of (potentially) infectious and/or recent HBV infections versus unnecessary donor loss, was evaluated for each of the three HBV screening tests., Results: HBV donor screening identified 89 HBV-infected donors with at least two reactive HBV markers (MP-NAT, HBsAg and/or anti-HBc). Single HBV-marker yield was: 5 MP-NAT-only, 0 HBsAg-only, and 20 anti-HBc-only donors. In addition, anti-HBc screening yielded 1,067 potentially infectious donors at risk for occult HBV infection (OBI). In total, 4,126 (0.71%) donors were anti-HBc-reactive at first-time screening, and 1,098 (0.19%) seroconverted during follow-up. Anti-HBc-related donor loss was limited to 2,627 (0.45%) donors using anti-HBs titers and two-strike programs. Donor loss due to MP-NAT and HBsAg screening was extremely low: 0 and 128 donors, respectively., Conclusion: HBV donor screening could be limited to MP-NAT and anti-HBc screening. MP-NAT and anti-HBc improved blood safety by intercepting infectious donations from donors with recent infection or OBI, while HBsAg did not. Unnecessary donor loss related to anti-HBc screening is substantial but does not endanger the continuity of the blood supply., (© 2021 AABB.)
- Published
- 2021
- Full Text
- View/download PDF
9. Can we prevent vasovagal reactions in young inexperienced whole blood donors? A placebo controlled study comparing effects of a 330 vs 500 mL water drink prior to donation.
- Author
-
Wiersum-Osselton J, Romeijn B, van den Brekel E, van Dongen A, Hermans F, Bokhorst A, and Marijt-van der Kreek T
- Subjects
- Adolescent, Adult, Blood Pressure, Female, Humans, Male, Syncope, Vasovagal etiology, Syncope, Vasovagal physiopathology, Blood Donors, Drinking Water administration & dosage, Surveys and Questionnaires, Syncope, Vasovagal prevention & control
- Abstract
Background: Complications of donation reduce donor return. Younger and less experienced donors are more likely to experience vasovagal-type reactions (VVR). A water drink of approximately 500 mL shortly before donation may reduce VVR, but the effect of a smaller volume of water has not been investigated., Study Design and Methods: A placebo-controlled comparative study was conducted among donors < 30 years who attended for a 1st-4th whole blood (WB) donation. Collection centers were assigned to offer one of three interventions: 500 mL water drink, 330 mL water drink, or a placebo intervention consisting of pre-donation arm exercise. Within 7 days after attending, participants received an electronic questionnaire about possible symptoms during and after donation. In additional centers, control donors were recruited, who only received standard care and were also sent the questionnaire. Self-reported VVR and other complications were evaluated in all groups., Results: Out of 8,300 participating donors, 6,921 (83%) returned the questionnaire. Overall, 18.5% of responding donors reported moderate or worse VVR symptoms. In 2nd-4th time donors, both water volumes decreased the odds of a VVR compared to standard care controls (OR
500ml 0.75, 95% CI 0.59-0.94; OR330ml 0.73, 0.58-0.91; adjusted combined OR 0.77, 0.64-0.94). There was no effect in new donors or the placebo group compared to controls., Conclusion: In young donors making their 2nd-4th WB donation, drinking water was associated with 23% fewer VVR with no difference between 330 and 500 mL. This decrease was not found in the placebo group. The findings support advocating drinking water for the prevention of VVR., (© 2018 AABB.)- Published
- 2019
- Full Text
- View/download PDF
10. Two decades of risk factors and transfusion-transmissible infections in Dutch blood donors.
- Author
-
Slot E, Janssen MP, Marijt-van der Kreek T, Zaaijer HL, and van de Laar TJ
- Subjects
- Adult, Deltaretrovirus Infections diagnosis, Deltaretrovirus Infections epidemiology, Deltaretrovirus Infections etiology, Deltaretrovirus Infections transmission, Female, HIV Infections diagnosis, HIV Infections epidemiology, HIV Infections etiology, HIV Infections transmission, Hepatitis B diagnosis, Hepatitis B epidemiology, Hepatitis B etiology, Hepatitis B transmission, Hepatitis C diagnosis, Hepatitis C epidemiology, Hepatitis C etiology, Hepatitis C transmission, Humans, Incidence, Male, Middle Aged, Netherlands epidemiology, Prevalence, Risk Factors, Syphilis diagnosis, Syphilis etiology, Syphilis transmission, Virus Diseases diagnosis, Virus Diseases etiology, Virus Diseases transmission, Blood Donors statistics & numerical data, Blood Safety methods, Donor Selection methods, Syphilis epidemiology, Virus Diseases epidemiology
- Abstract
Background: Risk behavior-based donor selection procedures are widely used to mitigate the risk of transfusion-transmissible infections (TTIs), but their effectiveness is disputed in countries with low residual risks of TTIs., Study Design and Methods: In 1995 to 2014, Dutch blood donors infected with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), or syphilis were interviewed by trained medical counselors to identify risk factors associated with TTIs. Trends in the prevalence and incidence of TTIs were analyzed using binomial regression models., Results: A total of 972 new donors and 381 repeat donors had TTIs. New donors had higher rates of TTIs compared to repeat donors. Although the HBV and HCV prevalence gradually decreased over time, the incidence of all five TTIs remained stable during the past two decades. In new donors the TTIs had the following risk profiles: "blood-blood contact" for HCV, "unprotected sex" for HIV and syphilis, and "country of birth" for HBV and HTLV. In infected repeat donors, sexual risk factors predominated for all TTIs. At posttest counseling, 28% of infected repeat donors admitted to risk factors leading to permanent donor exclusion if revealed during the donor selection procedure (predominantly male-to-male sex and recent diagnosis of syphilis)., Conclusion: The prevalence and incidence of TTIs among Dutch blood donors are six- to 60-fold lower than in the general Dutch population, illustrating the effectiveness of donor selection procedures. However, at least a quarter of infected donors appeared noncompliant to the donor health questionnaire (DHQ), suggesting that DHQs, or the way donor questioning is implemented, can be improved., (© 2015 AABB.)
- Published
- 2016
- Full Text
- View/download PDF
11. The yield of universal antibody to hepatitis B core antigen donor screening in the Netherlands, a hepatitis B virus low-endemic country.
- Author
-
van de Laar TJ, Marijt-van der Kreek T, Molenaar-de Backer MW, Hogema BM, and Zaaijer HL
- Subjects
- Adult, Blood Safety, False Positive Reactions, Female, Hepatitis B blood, Hepatitis B transmission, Hepatitis B Surface Antigens blood, Humans, Male, Netherlands epidemiology, Nucleic Acid Amplification Techniques, Prevalence, RNA, Viral blood, Viremia blood, Donor Selection, Hepatitis B epidemiology, Hepatitis B Antibodies blood, Hepatitis B Core Antigens immunology, Viremia epidemiology
- Abstract
Background: In the Netherlands, universal antibody to hepatitis B core antigen (anti-HBc) donor screening was introduced in July 2011 to intercept potentially infectious donations slipping through hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA minipool screening (HBV DNA MP6)., Study Design and Methods: The yield and donor loss were evaluated after the first 2 years of universal anti-HBc donor screening. A total of 382,173 donors were tested for anti-HBc and, if positive, for antibody to HBsAg (anti-HBs). Anti-HBc-reactive donors with anti-HBs of less than 200 IU/L were deferred, but repeat donors were allowed retesting after 6 months if anti-HBs was less than 10 IU/mL. Anti-HBc false positivity was estimated using the crude anti-HBc signal, family name-based ethnicity scoring, and donor follow-up., Results: Anti-HBc screening identified 13 confirmed or potential HBsAg- and HBV DNA MP6-negative recent HBV infections. In addition, 820 anti-HBc-reactive donors with low anti-HBs titers (<200 IU/mL), potentially harboring occult HBV infection (OBI), were identified and deferred. Overall, 1583 (0.41%) donors were deferred: 1178 (0.31%) during first-time anti-HBc screening, 361 (0.09%) anti-HBc seroconverters, and 44 (0.01%) donors with waning anti-HBs titers. Only 188 of 1583 (12%) deferred donors could be reentered upon retesting. Estimated anti-HBc false positivity was 16%, but varied greatly among anti-HBc-reactive donors with and without anti-HBs (8% vs. 62%)., Conclusion: Anti-HBc testing has improved the safety of the Dutch blood supply but its exact yield remains difficult to determine, due to the complexity of confirming anti-HBc reactivity and OBI. In a low-endemic country, donor loss associated with anti-HBc screening is sustainable, but adds to the already considerable list of donor exclusions., (© 2014 AABB.)
- Published
- 2015
- Full Text
- View/download PDF
12. Cost-effectiveness of questionnaires in preventing transfusion-transmitted infections.
- Author
-
de Kort W, van den Burg P, Geerligs H, Pasker-de Jong P, and Marijt-van der Kreek T
- Subjects
- Blood Donors statistics & numerical data, Humans, Netherlands, Surveys and Questionnaires, Transfusion Reaction
- Abstract
Background: The cost-effectiveness of the donor health questionnaire (DHQ) as a tool to assess donor eligibility has not been quantified. This study focused on cost-effectiveness of the DHQ in preventing transfusion-transmitted infections (TTIs)., Study Design and Methods: Data on whole blood donor eligibility assessments in the Netherlands in 2008 to 2010 were analyzed. Based on test results and epidemiologic data on TTIs, the number of donor visits in their window phase was calculated. Subsequently, the incremental cost-effectiveness ratio (ICER) of the DHQ was calculated., Results: The overall annual deferral rate in the study period was 9.6% (9.3%-10.0%). The annual deferral rate for TTI risk was 0.86% (0.82%-0.89%). Taking into account the number of self-deferrals, deferral rate for TTI risk in all donors was 1.90% (1.81%-2.02%). The calculated annual numbers of prevented cases of TTI were hepatitis B, 0.142; hepatitis C, 0.010; human immunodeficiency virus, 0.016; and syphilis, 0.135. The annual costs for TTI risk-related eligibility assessments, deferrals, and substitutions were €84,807 (€55,193-€123,811) for the blood establishment (BE) and €90,501 (€46,965-€159,571) for deferred donors. Annual savings were €991 (€276-€2325), while annual quality-adjusted life-years (QALYs) gained were 0.120 (0.059-0.226). Hence, the ICER for the DHQ on preventing TTIs was €696,744 (€315,422-€1,611,681) for BE costs only and €1,449,055 (€669,439-€3,145,961) including costs for deferred donors., Conclusion: The DHQ enhances self-selection and should not be abandoned. However, the DHQ is not a cost-effective tool for further reducing TTIs. The high costs per case prevented and the small number of QALYs gained argue against maintaining deferral policy through the DHQ at the current level., (© 2013 American Association of Blood Banks.)
- Published
- 2014
- Full Text
- View/download PDF
13. Risk factors for complications in donors at first and repeat whole blood donation: a cohort study with assessment of the impact on donor return.
- Author
-
Wiersum-Osselton JC, Marijt-van der Kreek T, Brand A, Veldhuizen I, van der Bom JG, and de Kort W
- Subjects
- Adolescent, Adult, Aged, Anthropometry, Blood Flow Velocity, Female, Hematoma epidemiology, Hemoglobins analysis, Humans, Male, Middle Aged, Netherlands, Pain epidemiology, Retrospective Studies, Risk Factors, Sex Distribution, Syncope, Vasovagal epidemiology, Young Adult, Blood Donors psychology, Hematoma etiology, Pain etiology, Punctures adverse effects, Syncope, Vasovagal etiology
- Abstract
Background: First-time donation is among recognised risk factors for vasovagal reactions to blood donation and reactions are known to reduce donor return. We assessed associations between potential risk factors and vasovagal reactions and needle-related complications in first-time whole blood donation in comparison to repeat donation and analysed the impact of complications on donor return., Materials and Methods: We performed a cohort study on whole blood donations in The Netherlands from 1/1/2010 to 31/12/2010 using data extracted from the blood service information system. Donation data up to 31/12/2011 were used to ascertain donor return., Results: In 2010 28,786 donors made first whole blood donations and there were 522,958 repeat donations. Vasovagal reactions occurred in 3.9% of first donations by males and 3.5% of first donations by females compared to in 0.2% and 0.6%, respectively, of repeat donations. Associations of vasovagal reactions with other factors including age, body weight, systolic and diastolic blood pressure were similar in first-time and repeat donors. Needle-related complications occurred in 0.2% of male and 0.5% of female first-time donations and in 0.1% and 0.3%, respectively, of repeat donations. Among first-time donors, the return rate within 1 year was 82% following an uncomplicated first donation, but 55% and 61% following vasovagal reactions and needle-related complications, respectively; the corresponding percentages among repeat donors were 86%, 58% and 82%., Discussion: Among first-time donors, females suffered less than males from vasovagal reactions. Other risk factors had similar associations among first-time and repeat donors. Vasovagal reactions and needle-related complications in both first-time and repeat donors are followed by reduced donor return.
- Published
- 2014
- Full Text
- View/download PDF
14. Donor vigilance: what are we doing about it?
- Author
-
Wiersum-Osselton JC, Marijt-van der Kreek T, and de Kort WL
- Subjects
- Databases, Factual statistics & numerical data, Humans, Phlebotomy adverse effects, Risk Factors, Syncope, Vasovagal etiology, Syncope, Vasovagal prevention & control, Blood Donors, Monitoring, Physiologic methods, Monitoring, Physiologic statistics & numerical data
- Abstract
Donor vigilance is the systematic monitoring of adverse reactions and incidents in blood donor care with a view to improving quality and safety for blood donors. Standard international definitions are available for surveillance purposes. In recent years advances have been made in determining risk factors for vasovagal and other adverse reactions to blood donation as well as in evaluating preventive measures. Blood establishments should record all adverse reactions in blood donors. Besides its use for individual donor care, this information can be reviewed within and between organisations to guide policy decisions and research for improving donor care., (Copyright © 2011 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.